Tezepelumab administration in moderate-to-severe uncontrolled asthma: Is it all about eosinophils?

Pier Giorgio Puzzovio, Ron Eliashar, Francesca Levi-Schaffer*

*Corresponding author for this work

Research output: Contribution to journalEditorial

6 Scopus citations
Original languageAmerican English
Pages (from-to)1582-1584
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Issue number5
Early online date8 Feb 2022
StatePublished - May 2022

Bibliographical note

Funding Information:
This study was supported by Rosetrees Trust (UK), Aimwell Charitable Trust (UK), Israel Science Foundation (grant no. 442/18 ), Israel Ministry of Science & Technology , and Emalie Gutterman Memorial Endowed Fund for COPD Related Research .


  • Allergic effector unit
  • TSLP
  • airway hyperresponsiveness
  • allergic inflammation
  • asthma
  • eosinophils
  • mast cells
  • Cytokines
  • Humans
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Asthma/drug therapy
  • Leukocyte Count
  • Eosinophils

Cite this